Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Avacta LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 36.30p 67,418 00:00:00
Bid Price Offer Price High Price Low Price Open Price
35.60p 37.00p 36.30p 36.30p 36.30p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.76 -10.39 -13.49 42.1

Avacta (AVCT) Latest News

More Avacta News
Avacta Takeover Rumours

Avacta (AVCT) Share Charts

1 Year Avacta Chart

1 Year Avacta Chart

1 Month Avacta Chart

1 Month Avacta Chart

Intraday Avacta Chart

Intraday Avacta Chart

Avacta (AVCT) Discussions and Chat

Avacta (AVCT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16:11:0135.705,0001,785.00O
16:09:2035.6719,5346,967.78O
16:03:5136.907,5002,767.50O
14:52:5336.4516,4605,999.67O
14:38:3935.671,078384.52O
View all Avacta trades in real-time

Avacta (AVCT) Top Chat Posts

DateSubject
22/3/2019
08:20
Avacta Daily Update: Avacta is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 36.30p.
Avacta has a 4 week average price of 35.40p and a 12 week average price of 28.20p.
The 1 year high share price is 50.50p while the 1 year low share price is currently 21.20p.
There are currently 115,956,471 shares in issue and the average daily traded volume is 118,699 shares. The market capitalisation of Avacta is £42,092,198.97.
15/3/2019
12:41
hampton58: ThxYes it be a very exciting Q2/Q3 with plenty of news flow which will drive the price north.Barclays and Cowen life science conferences had some very bullish presentations by the majors and their plans for the sector.You should applied some read across valuation and you will get some very different share price.
26/2/2019
11:32
cf456: What would another multi million pound deal like LG Chem do to the share price I wonder? Especially now that the story is a lot more bullish. --- "Moreover, a number of major pharma/biotech companies are nearing the end of a significant period of validation of Affimers against their specific targets, and it is likely that more deals will be announced in 2019" hTTps://www.avacta.com/sites/default/files/resource/AVCT%20%E2%80%93%20Moderna%20%E2%80%93%2006%20February%202019.pdf
23/2/2019
09:31
cf456: Bumpa33 - yes, it's definitely a different proposition to the usual and one where the potential upside is very significant indeed. And excitingly a lot of that is in the near term. "Significant milestones should be achieved in the near future that would support considerable valuation uplift and bring Avacta inline with comparators." The CEO is keen to differentiate the company from typical bio/pharma companies: "Affimer is a platform technology capable of generating a continuous pipeline of products. Unlike classic biotech companies Avacta has downside protection from its reagents business which generates recurring revenue." hTTps://www.avacta.com/sites/default/files/resource/AVACTA%20TPI%20October%201%202018.pdf It's a great risk:reward play and the analysts know it with finnCap's latest 125p target showing the way. Multiples of the current share price. hTTps://www.avacta.com/sites/default/files/resource/Avacta%20MN%20040219.pdf The company has made significant strides in recent months with the LG Chem deal showing the kind of money big pharma is prepared to commit to the tech. Multiple similar deals are expected in the months ahead and understandably the company is very bullish with regards its future: "I look forward to updating the market on progress during 2019 which I expect to be a year of very significant progress for the Company." hTTps://investegate.co.uk/avacta-group-plc--avct-/rns/agm-business-update-and-notice-of-results/201901210700045586N/
04/2/2019
11:32
hampton58: AgreeOne would expect several new license dealsAs both Moderna and LG have done extensive DD etc on Avacta and the current share price does not reflect at all the potential and the very realistic scenario of several more $300 mill license deals being signed this year, the OEM's needs to find new revenue sources and Avacta is attracting a lot of interest .If you would to apply a US listed immuno Oncology valuation , then you have a share price of 250pOnce the human trials starts , there will be no stock available. None !!!
30/1/2019
14:13
cf456: Yes, the long game where the big profits are to be made in AVCT. The move since the LG Chem deal is just a taster of the much larger move that will unfold as time passes imo. The recent AGM Business update statement gave some hints as to the likely newsflow in the coming months. There are multiple catalysts, each with the potential to drive the share price very much higher. The upwards momentum has only just started. --- "I look forward to updating the market on progress during 2019 which I expect to be a year of very significant progress for the Company." "As we expand those data-sets across our in-house programmes I am very confident that we will see additional significant licensing deals that transform the Company." Tufts collaboration - "This is an exciting prospect that has got numerous large pharmaceutical partners interested in the Affimer TMACTM programme." "The licensing deal with New England Biolabs is a perfect example of the type of deals we have in the pipeline of Affimer reagent evaluations and I expect that we will see more of these deals emerge in 2019 with both large and small partners across multiple markets." hTTps://investegate.co.uk/avacta-group-plc--avct-/rns/agm-business-update-and-notice-of-results/201901210700045586N/
23/1/2019
19:42
cf456: Poor attempt at a deramp there. Today's volume is low. There has been no heavy selling, just a little bit of profit taking in a strong uptrend. The price has moved up 100% since December and in the past couple of days hit multi-month highs. Quite understandable that some feel tempted to take profits. The fun has barely started here. LG Chem the first of multiple anticipated deals. Looking forward to much greater share price appreciation in the coming months. Fully expect retracements along the way. Nothing moves in a straight line. But the trend is now up and multiples of the current share price over time can be expected.
07/1/2019
10:53
cf456: Decent sized £16k buy delayed from earlier. A few more of those would help get the share price moving upwards again. Makes sense to follow the instis who have been loading up and buy in cheaply before the newsflow takes the share price very much higher. "With probably close to 50 companies that have or are undertaking evaluations we expect further licence deals to be announced in 2018 and onwards, all of which should generate incremental value." - finnCap
31/12/2018
00:21
hampton58: AgreeI believe we will see a second deal being announced with similar upfront and milestone payments The share price reflects a historic share share where the very same shareholder is now buying !!40 p is just the beginning Have a a good AVCT 2019
30/12/2018
15:37
bumpa33: Malcolm Stacey, long time follower of AVCT gives his reasoning for picking them as one of his tips of the year. Nothing we don’t really know already... Between now and January 2nd we shall be publishing more than 20 share tips of the year – buys and sells. Second up is one from Malcolm Stacey. Hello Share Trouncers. Investing in medical pioneers - especially smaller ones - is one of the riskiest ploys you can adopt in Shareland. But the rewards are usually glittering. Probably the best-placed modest pharma in my collection at the mo is Avacta (AVCT). For a long time now the share price has slowly decayed. That’s the fate of many a penny share which hasn’t been able to publish recent good news. However, all that’s changed in the last few weeks. Firstly, let me explain why Avacta has been raising interest in the medical world. It produces affimers. These are alternatives to antibodies. The latter are produced in animals to treat diseases, some of them serious. The advantages of artificial antibodies is that they don't have to be produced in animals, they are more stable and probably cheaper to develop. The market is worth billions and a big South Korean pharma, LG Group, has realised this. It is investing up to £180 million pounds in Avacta. And that’s good because we all know medical research is acutely expensive. On top of this, the deal allows the Wetherby firm to collect royalties. On the heels of this welcome news came tiding that a big new cheese was being appointed from the Swiss giant Roche. He is Doctor Jose Saro, who’ll oversee the affirmer project. And by all accounts this chap really knows how to develop new treatments. These people would not be scrambling onto Avacta’s bandwagon if they had not researched the possibilities throughly. As lay people we cannot make a judgement on the usefulness of affimers. But these heavy-hitters know their stuff and we can probably attach high value to their support. The share price leapt on December’s news. But it’s fallen slightly since. And I really don't think the market has realised the potential - yet.
28/12/2018
10:28
74tom: Disagree that it depends on the markets, unless we have an armageddon event. With a 33m Mcap if the positive news flow continues in 2019 the current share price will increase considerably. Trading is fine but it’s such behaviour that has held the current share price below 33p since the LG deal, as every time we get momentum a rash of 10% profit taking occurs. The simplest rule that allows the price to rise and derisks fully it to sell half when the price doubles, leaving a free carry on the remainder.
Avacta share price data is direct from the London Stock Exchange
Your Recent History
LSE
AVCT
Avacta
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190322 16:31:54